Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PROGNOSTIC FACTORS IN PATIENTS WITH PLEURAL MESOTHELIOMA - THE ON-FOR-RESEARCH-AND-TREATMENT-OF-CANCER-EXPERIENCE
Autore:
CURRAN D; SAHMOUD T; THERASSE P; VANMEERBEECK J; POSTMUS PE; GIACCONE G;
Indirizzi:
VRIJE UNIV AMSTERDAM,ACAD ZIEKENHUIS,DEPT ONCOL,BOELELAAN 1117 NL-1081 HV AMSTERDAM NETHERLANDS VRIJE UNIV AMSTERDAM,ACAD ZIEKENHUIS,DEPT ONCOL NL-1081 HV AMSTERDAM NETHERLANDS EUROPEAN ORG RES TREATMENT CANC,CTR DATA BRUSSELS BELGIUM UNIV ZIEKENHUIS ANTWERPEN ANTWERP BELGIUM
Titolo Testata:
Journal of clinical oncology
fascicolo: 1, volume: 16, anno: 1998,
pagine: 145 - 152
SICI:
0732-183X(1998)16:1<145:PFIPWP>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL LUNG-CANCER; DIFFUSE MALIGNANT MESOTHELIOMA; COOPERATIVE GROUP; CERVICAL-CANCER; PHASE-II; EXTRAPLEURAL PNEUMONECTOMY; MULTIMODALITY THERAPY; CONSECUTIVE PATIENTS; REGRESSION-MODELS; ONCOLOGY-GROUP;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
57
Recensione:
Indirizzi per estratti:
Citazione:
D. Curran et al., "PROGNOSTIC FACTORS IN PATIENTS WITH PLEURAL MESOTHELIOMA - THE ON-FOR-RESEARCH-AND-TREATMENT-OF-CANCER-EXPERIENCE", Journal of clinical oncology, 16(1), 1998, pp. 145-152

Abstract

Purpose: Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data. Patients and Methods: From October 1984 to October 1993, 204 eligible adult patients with malignant pleural mesothelioma were entered into five consecutive prospective European Organization for Researchand Treatment of Cancer (EORTC) phase II clinical trials designed to assess the efficacy of various anticancer drugs (mitoxantrone, epidoxorubicin, etoposide, and paclitaxel). The Cox model war used to assess 13 factors related to biology and disease history with respect to survival. Results: The median survival duration was 12.6 months from diagnosis and 8.4 months from trial entry, In the multivariate analysis, poor prognosis was associated with a poor performance status, a high WBCcount, a probable/possible histologic diagnosis of mesothelioma, malegender, and having sarcomatous tissue as the histologic subtype. Taking these five factors into consideration, patients were classified into two groups: a good-prognosis group (1-year survival rate, 40%; 95% confidence interval [CI], 30% to 50%) and a poor-prognosis group (1-year survival, 12%; 95% CI, 4% to 20%). Conclusion: These results may help to design new clinical trials in pleural mesothelioma by selecting more homogenous groups of patients. (C) 1998 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 07:31:10